Laafon Galaxy Pharmaceuticals · Tablets · Prescription only
Ceffon-200 — Cefixime 200 mg with Lactic Acid Bacillus
Ceffon-200 is an oral third-generation cephalosporin tablet marketed by Laafon Galaxy Pharmaceuticals. Cefixime is a Schedule H1 drug in India: it may be supplied only against the prescription of a registered medical practitioner, and the supply must be entered in the Schedule H1 register.
- CompositionCefixime 200 mg + Lactic acid bacillus 60 million spores
- Dosage formFilm-coated tablet, oral
- Pack10 × 10 Alu-Alu, drip-off carton
- MRP₹152.00 per strip of 10
- ScheduleH1 (entry 9)
- StorageStore below 30 °C, protect from light and moisture
Schedule H1 — what the label and the counter must carry
Cefixime is listed at entry 9 of Schedule H1 to the Drugs and Cosmetics Rules, 1945, inserted by notification G.S.R. 588(E) of 30 August 2013.[3] The pack must carry the boxed Schedule H1 warning and the Rx symbol, and the retailer must record the prescriber, the patient and the quantity supplied in a separate register retained for three years. Laafon does not sell Ceffon-200 to the public: enquiries on this page are for distribution, PCD franchise and contract-manufacturing partners. See our Schedule H1 drug list and register rules for the full compliance position.
What cefixime actually covers — and what it does not
This is the most misunderstood point about oral third-generation cephalosporins. Cefixime has enhanced Gram-negative activity and deliberately narrow Gram-positive activity. The approved product information states plainly that Pseudomonas species, Enterococcus species, Group D streptococci, Listeria monocytogenes, most strains of staphylococci including methicillin-resistant strains, most strains of Enterobacter, most strains of Bacteroides fragilis and most strains of Clostridium are resistant to cefixime.[1] Among Gram-positives, only Streptococcus pneumoniae and Streptococcus pyogenes appear in the susceptible list.[1]
1 · Suspected or confirmed organism
2 · Site of infection
Select an organism and a site
This reference tool maps the approved product information onto the organism and site you select. It supports a prescriber’s decision; it does not replace culture, sensitivity testing or clinical judgement.
Pharmacology, safety and regulatory position
Mechanism
Cefixime is bactericidal. It binds penicillin-binding proteins and blocks the final transpeptidation step of peptidoglycan cross-linking, so the growing cell wall cannot be completed and the organism lyses.[1] Its stability to many beta-lactamases is what gives the molecule its Gram-negative reach.
Pharmacokinetics
Scroll sideways on a phone to see every column.
| Parameter | Value | Note |
|---|---|---|
| Oral absorption | 40–50 % | Absorbed to the same extent with or without food |
| Effect of food | Delays, does not reduce | Time to maximal absorption increases by roughly 0.8 hours when taken with food |
| Time to peak | 2–6 h | Tablet and suspension |
| Serum half-life | 3–4 h | Average; may extend to 9 hours, and further in renal impairment |
| Protein binding | ≈ 65 % | Moderate, concentration-independent |
| Suspension vs tablet | 25–50 % higher peak | Suspension produces the higher peak concentration; the forms are not interchangeable milligram for milligram |
Why lactic acid bacillus is in the tablet
Ceffon-200 is a fixed-dose combination of cefixime with 60 million spores of lactic acid bacillus, included with the intention of limiting antibiotic-associated disturbance of gut flora. Treat this as a formulation rationale, not a proven clinical outcome: the approved cefixime product information makes no claim of this kind, and the combination is not part of the cefixime monograph. It also means Ceffon-200 is not plain Cefixime Tablets IP — see the regulatory tab.
Adverse effects
The commonest are gastrointestinal: diarrhoea, loose stools, nausea, vomiting, abdominal pain, flatulence and dyspepsia.[2] Hypersensitivity reactions occur, and anaphylactic or anaphylactoid reactions including shock and fatalities have been reported with cefixime.[1]
Two events that need urgent attention
Clostridioides difficile-associated diarrhoea has been reported with nearly all antibacterials including cefixime, and can present up to two or more months after the course finishes. Watery or bloody stools, cramps or fever during or after treatment must be reviewed, not self-treated with an antimotility agent.[1][2] Any rash, hives, swelling or breathing difficulty should stop the drug immediately.[2]
Documented interactions
- Carbamazepine — elevated carbamazepine levels have been reported on concomitant use; monitoring is advised.[1]
- Warfarin and other anticoagulants — increased prothrombin time, with or without clinical bleeding, has been reported.[1]
- Hormonal contraceptives — cefixime may reduce their effectiveness; an additional method should be used during and shortly after the course.[2]
- Urine glucose testing — false-positive reactions occur with Clinitest, Benedict’s solution and Fehling’s solution. Enzyme-based glucose tests are unaffected. A false-positive direct Coombs test has been reported with cephalosporins.[1]
On alcohol
No disulfiram-like interaction of the kind seen with some other cephalosporins is described for cefixime in the approved product information. That is not a recommendation to drink during an antibiotic course, and it is not a substitute for the prescriber’s advice for a given patient. The earlier version of this page carried an unsourced statement encouraging habitual drinkers to continue; it has been removed.
Reference figures from the approved product information, for prescribers and dispensing pharmacists. The prescriber sets the dose and duration for the individual patient.
Scroll sideways on a phone to see every column.
| Population | Reference dose | Note |
|---|---|---|
| Adults and children over 45 kg or over 12 years | 400 mg daily | As a single daily dose or divided twelve-hourly. Two Ceffon-200 tablets make up the 400 mg daily total. |
| Children 6 months and older, up to 45 kg | 8 mg/kg/day | A suspension is the appropriate form at this weight, not a 200 mg tablet. See Ceffon Dry Syrup. |
| Creatinine clearance 60 mL/min or above | Standard dose | No adjustment stated |
| Creatinine clearance 21–59 mL/min | Reduced dose | Dose reduction required per the product information |
| Creatinine clearance 20 mL/min or below | Further reduction | Cefixime is not removed in significant quantity by dialysis |
| Uncomplicated urogenital gonorrhoea | See note | The product information gives a single 400 mg oral dose; current CDC guidance recommends ceftriaxone 500 mg intramuscularly and treats oral cefixime 800 mg as an alternative only where ceftriaxone is unavailable.[1][4] |
Gonorrhoea: the guidance has moved
Cefixime is no longer a first-line gonorrhoea treatment. CDC lists ceftriaxone 500 mg intramuscularly as the recommended regimen and reserves oral cefixime 800 mg as an alternative when ceftriaxone cannot be given, noting that cefixime does not achieve blood levels as high or as sustained as ceftriaxone and shows limited efficacy at pharyngeal sites, with a 92.3 % cure rate. Rising cefixime minimum inhibitory concentrations in surveillance isolates are the reason.[4]
Schedule status
Cefixime sits at entry 9 of Schedule H1, inserted into the Drugs and Cosmetics Rules, 1945 by G.S.R. 588(E) dated 30 August 2013 and in force from 1 March 2014.[3] Schedule H1 is amended by gazette notification and the list has grown since — the most recent addition at the time of writing is pregabalin at entry 51, by G.S.R. 377(E) of 13 May 2026. Check the current list before relying on any classification.
Price control
Cefixime is a scheduled formulation under the Drugs (Prices Control) Order, 2013. The ceiling price notified for Cefixime Tablet 200 mg is ₹10.01 per tablet under S.O. 1575(E) dated 25 March 2026, effective 1 April 2026 — that is ₹100.10 for a strip of ten, exclusive of GST.[5] Our NPPA DPCO 2026 ceiling price index carries the full list.
Why this matters for a cefixime combination
That ceiling is notified against plain Cefixime Tablet 200 mg. Whether a fixed-dose combination of cefixime with lactic acid bacillus is a scheduled formulation for ceiling-price purposes, or a non-scheduled formulation governed instead by the annual increase cap in the DPCO, turns on how the specific product is categorised by NPPA — not on the strength of the cefixime component alone. Distributors should hold the product’s own price-approval documentation on file rather than infer it.
Nomenclature
Ceffon-200 is a cefixime combination and is described here as such. Where marketing material, packaging or a listing describes the product as Cefixime Tablets IP 200 mg, that wording denotes a single-ingredient product complying with the Indian Pharmacopoeia monograph for cefixime tablets, which a combination containing lactic acid bacillus is not.
The Ceffon cefixime range
Scroll sideways on a phone to see every column.
| Brand | Composition | Pack | Typical use |
|---|---|---|---|
| Ceffon-200 | Cefixime 200 mg + lactic acid bacillus 60 million spores | 10 × 10 Alu-Alu | Adults and children over 45 kg |
| Ceffon-OX | Cefixime 200 mg + ofloxacin 200 mg + lactic acid bacillus | 10 × 10 Alu-Alu | Where a fluoroquinolone is clinically indicated alongside cefixime |
| Ceffon Dry Syrup | Cefixime 50 mg per 5 mL after reconstitution | Dry powder for oral suspension | Paediatric dosing by body weight |
Cross-brand comparison of cefixime 200 mg products in the Indian market, including current pricing against the NPPA ceiling, is maintained on the molecule guide rather than duplicated here: Top 10 cefixime tablets in India.
Frequently asked questions
Strength is the wrong frame; spectrum is the right one. Cefixime is a potent oral agent against susceptible Gram-negative organisms such as Escherichia coli, Proteus mirabilis, Haemophilus influenzae and Moraxella catarrhalis, and against Streptococcus pneumoniae and Streptococcus pyogenes. It is not active against Staphylococcus aureus, Pseudomonas or Enterococcus, so in a staphylococcal skin or soft-tissue infection it is not a weaker choice — it is the wrong choice.
Yes. Cefixime is absorbed to the same extent with or without food — 40 to 50 per cent of an oral dose. Food delays rather than reduces absorption, increasing the time to maximal absorption by roughly 0.8 hours. Taking the tablet with food is a reasonable way to reduce nausea without compromising the dose.
No. Cefixime is a Schedule H1 drug in India. It may be supplied only against the prescription of a registered medical practitioner, the prescription must be retained for three years, and the supply must be recorded in a separate Schedule H1 register showing the prescriber, the patient and the quantity dispensed. The pack must carry the boxed Schedule H1 warning.
Not as a first choice, and this has changed. Current CDC guidance recommends ceftriaxone 500 mg intramuscularly as a single dose and treats oral cefixime 800 mg as an alternative reserved for when ceftriaxone cannot be given. Cefixime does not achieve blood levels as high or as sustained as ceftriaxone and its efficacy at pharyngeal sites is limited, with a reported cure rate of 92.3 per cent.
The ceiling price notified for Cefixime Tablet 200 mg is ₹10.01 per tablet under S.O. 1575(E) dated 25 March 2026, effective from 1 April 2026, exclusive of goods and services tax. That is a ceiling for the plain single-ingredient formulation, not a recommended price, and how it applies to a cefixime combination product depends on that product’s own categorisation under the Drugs (Prices Control) Order.
Children aged six months and older who weigh 45 kg or less are dosed by body weight at 8 mg per kg per day, which a fixed 200 mg tablet cannot deliver accurately. An oral suspension is the appropriate form. Children over 45 kg or older than twelve years receive the adult dose. Note that a suspension produces a peak concentration 25 to 50 per cent higher than the same milligram dose as a tablet, so the two are not interchangeable.
सेफिक्सिम 200 एमजी टैबलेट — संक्षिप्त जानकारी
Ceffon-200 में सेफिक्सिम 200 मिग्रा और लैक्टिक एसिड बैसिलस 60 मिलियन स्पोर होते हैं। यह तीसरी पीढ़ी का सेफलोस्पोरिन एंटीबायोटिक है, जो बैक्टीरिया की कोशिका भित्ति बनने से रोककर काम करता है।
यह किन संक्रमणों के लिए स्वीकृत है: मूत्र मार्ग का साधारण संक्रमण, कान का मध्य संक्रमण, गले और टॉन्सिल का संक्रमण, और क्रॉनिक ब्रोंकाइटिस का तीव्र प्रकोप।
यह किन पर असर नहीं करता: स्टैफिलोकोकस ऑरियस (MRSA सहित), स्यूडोमोनास और एंटरोकोकस पर सेफिक्सिम प्रभावी नहीं है।
महत्वपूर्ण: सेफिक्सिम शेड्यूल H1 दवा है। यह केवल पंजीकृत चिकित्सक के पर्चे पर ही दी जा सकती है। दस्त, पेट दर्द, मतली या त्वचा पर चकत्ते हो सकते हैं। यदि दस्त में खून आए, तेज़ पेट दर्द हो या साँस लेने में तकलीफ़ हो तो तुरंत चिकित्सक से संपर्क करें।
यह जानकारी केवल शैक्षिक उद्देश्य के लिए है और चिकित्सकीय सलाह का विकल्प नहीं है।
Distribution, PCD franchise and contract manufacturing
Ceffon-200 is available to licensed distributors, PCD franchise partners and institutional buyers. Laafon Galaxy Pharmaceuticals works on a contract-manufacturing basis for this product. Being a Schedule H1 antibiotic, supply is to holders of a valid drug licence only — we do not sell to the public.
Related on Laafon
- Top 10 cefixime tablets in IndiaBrand-by-brand comparison, NPPA pricing and resistance data for the molecule.
- Schedule H1 drug list and register rulesAll 51 entries, the register format, and the gazette notifications that changed it.
- NPPA DPCO 2026 ceiling price indexSearchable ceiling prices for scheduled formulations after the 2026 WPI revision.
- Laafon tablet rangeEvery tablet brand we market, with composition and pack details.
- Ceffon Dry SyrupThe paediatric cefixime form, dosed by body weight.
- Ceffon-OXThe cefixime and ofloxacin combination in the same range.
References
- Lupin Pharmaceuticals. SUPRAX (cefixime) tablets, chewable tablets, capsules and oral suspension — full prescribing information. Silver Spring: US Food and Drug Administration; 2016. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202091s004,203195s005lbl.pdf Accessed August 2026.
- MedlinePlus. Cefixime. Bethesda: US National Library of Medicine, National Institutes of Health. Available from: https://medlineplus.gov/druginfo/meds/a690007.html Accessed August 2026.
- Ministry of Health and Family Welfare, Government of India. Notification G.S.R. 588(E) — insertion of Schedule H1 in the Drugs and Cosmetics Rules, 1945. The Gazette of India, Extraordinary, Part II, Section 3, Sub-section (i); 30 August 2013. In force 1 March 2014.
- Centers for Disease Control and Prevention. Gonococcal infections among adolescents and adults. Sexually Transmitted Infections Treatment Guidelines. Atlanta: CDC. Available from: https://www.cdc.gov/std/treatment-guidelines/gonorrhea-adults.htm Accessed August 2026.
- Drugs Control Department, Government of Kerala. NPPA updated price list as on 27 May 2026 — entry 170, Cefixime Tablet 200 mg, ceiling price ₹10.01 per tablet, notification S.O. 1575(E) dated 25 March 2026. Available from: https://dc.kerala.gov.in/wp-content/uploads/2026/06/NPPA-UPDATED-PRICE-LIST-AS-ON-27-05-2026.pdf Accessed August 2026.
Disclaimer. This page is technical and educational information for pharmacy, distribution and healthcare professionals. It is not medical advice and must not be used to diagnose or treat any condition. Cefixime is a prescription-only Schedule H1 medicine; a qualified registered medical practitioner must decide whether it is appropriate, at what dose and for how long. Prescribing guidance, schedule classifications and ceiling prices change by notification — verify against the current instrument before acting. Laafon Galaxy Pharmaceuticals does not supply prescription medicines to the public.
Medically Reviewed by:
Dr. Yogesh Chaudhary (B. Pharma)
Senior Pharmacist at S.N. Medical College, Agra-(UP)
